In addition, it has been shown that EZH2 inhibition is able to suppress leiomyosarcoma CSCs proprieties and retrieve the anti-tumor effect of PI3K/mTOR inhibition, supporting the therapeutic value of this combination [131]. The gene discussed is EZH2; the disease is leiomyosarcoma.